Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial.

What was studied

This study looked at the drug mepolizumab in people with nasal polyps. Their long-term sinus disease was severe and not under control. The work took place in 25 expert nose clinics in Italy. People got mepolizumab 100 mg every 4 weeks. Doctors checked polyp size, symptoms and sense of smell for 12 months. This was a phase 4 study done in everyday care.

What they found

In all, 621 people took part. After 12 months, polyp scores and symptom scores fell clearly. The main symptoms and the sense of smell got better. Still, 186 of 495 people had no sense of smell left. People who also had asthma improved more or faster. Disease control was reached in 206 of 519 people. Another 104 of 519 people were on the way to remission. Smaller polyps at the start were linked to moving towards remission. Side effects showed up in 29 of 621 people, most often grade 1.

What it means for patients

The authors say mepolizumab improved results step by step over 12 months. They say the drug was well tolerated in this group. These results come from everyday care in clinics. People who also had asthma seemed to gain more or sooner.

Why it is not certain yet

The results cover only the first year of treatment. The authors say longer studies are needed on control and remission. Part of the data was gathered by looking back in time. Not every person had data for every result. There was no comparison group, so effects are harder to judge.

Source

Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.